Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year
Generics Launches In 2022 Will ‘Affect The Second Half’ Of The Year
Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.
